Medicamen Biotech growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+21.7%+12.0%
EBITDA+41.4%−6.4%
Net Income+49.5%−12.7%
EPS (adj.)+35.7%−13.4%
Total Assets+25.3%+10.1%
Total Equity+29.5%+12.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MEDICAMEQ₹254.25

Medicamen Biotech Limited

· Pharma & Health
₹ CrorePeersMEDICOAAREYDRUGSNECLIFEHALEOSLABSALBERTDAVDNATCAPSUQVALIANTLABBALPHARMAMcap ₹345 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+21.7+12.0
EBITDA+41.4-6.4
Net Income+49.5-12.7
EPS (adj.)+35.7-13.4
Total Assets+25.3+10.1
Total Equity+29.5+12.5
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.